Membranous Nephropathy (MN), a leading cause of nephrotic syndrome in adults, has historically presented significant therapeutic challenges. Standard treatment protocols often involved prolonged courses of corticosteroids and cyclophosphamide, which, while effective for some, carried substantial side effect profiles and a risk of severe toxicity. The emergence of targeted biological agents...